Home The Word Brain My Amedeo FAQ Privacy About Flying Publisher   

COVID-19: Daily Top 10 Papers


  Free Subscription

Articles published in Clin Cardiol

Retrieve available abstracts of 28 articles:
HTML format

Single Articles

    October 2019
  1. SUN D, Cao YX, Li S, Guo YL, et al
    A modified algorithm with lipoprotein(a) added for diagnosis of familial hypercholesterolemia.
    Clin Cardiol. 2019;42:988-994.
    PubMed     Abstract available

  2. TOTH PP, Philip S, Hull M, Granowitz C, et al
    Hypertriglyceridemia is associated with an increased risk of peripheral arterial revascularization in high-risk statin-treated patients: A large administrative retrospective analysis.
    Clin Cardiol. 2019;42:908-913.
    PubMed     Abstract available

    June 2019
  3. KONISHI T, Sunaga D, Funayama N, Yamamoto T, et al
    Eicosapentaenoic acid therapy is associated with decreased coronary plaque instability assessed using optical frequency domain imaging.
    Clin Cardiol. 2019;42:618-628.
    PubMed     Abstract available

    January 2019
  4. CUI Y, Li S, Zhang F, Song J, et al
    Prevalence of familial hypercholesterolemia in patients with premature myocardial infarction.
    Clin Cardiol. 2019 Jan 13. doi: 10.1002/clc.23154.
    PubMed     Abstract available

  5. SUPERKO HR, Williams PT, Dansinger M, Schaefer E, et al
    Trends in low-density lipoprotein-cholesterol blood values between 2012 and 2017 suggest sluggish adoption of the recent 2013 treatment guidelines.
    Clin Cardiol. 2019;42:101-110.
    PubMed     Abstract available

    December 2018
  6. CHO HJ, Yoon JY, Kim N, Jang SY, et al
    Predictive value of a fragmented QRS complex in diagnosing patients with myocardial ischemia.
    Clin Cardiol. 2018 Dec 31. doi: 10.1002/clc.23148.
    PubMed     Abstract available

  7. WANG Y, Shen L, Xu D
    Aerobic exercise reduces triglycerides by targeting apolipoprotein C3 in patients with coronary artery disease.
    Clin Cardiol. 2018 Dec 3. doi: 10.1002/clc.23104.
    PubMed     Abstract available

    November 2018
  8. KOSKINAS KC, Windecker S, Buhayer A, Gencer B, et al
    Design of the Randomized, Placebo-Controlled Evolocumab for Early Reduction of LDL-Cholesterol Levels in Patients with Acute Coronary Syndromes (EVOPACS) Trial.
    Clin Cardiol. 2018 Nov 12. doi: 10.1002/clc.23112.
    PubMed     Abstract available

    October 2018
  9. NICHOLLS SJ, Lincoff AM, Bash D, Ballantyne CM, et al
    Assessment of omega-3 carboxylic acids in statin-treated patients with high levels of triglycerides and low levels of high-density lipoprotein cholesterol: Rationale and design of the STRENGTH trial.
    Clin Cardiol. 2018;41:1281-1288.
    PubMed     Abstract available

  10. STROES E, Robinson JG, Raal FJ, Dufour R, et al
    Consistent LDL-C response with evolocumab among patient subgroups in PROFICIO: A pooled analysis of 3146 patients from phase 3 studies.
    Clin Cardiol. 2018;41:1328-1335.
    PubMed     Abstract available

    September 2018
  11. LORENZATTI AJ, Eliaschewitz FG, Chen Y, Fialkow J, et al
    Rationale and design of a randomized study to assess the efficacy and safety of evolocumab in patients with diabetes and dyslipidemia: The BERSON clinical trial.
    Clin Cardiol. 2018;41:1117-1122.
    PubMed     Abstract available

    July 2018
  12. DE LUCA L, Arca M, Temporelli PL, Colivicchi F, et al
    Prevalence and Pharmacologic Management of Familial Hypercholesterolemia in an Unselected Contemporary Cohort of Patients With Stable Coronary Artery Disease.
    Clin Cardiol. 2018 Jul 23. doi: 10.1002/clc.23031.
    PubMed     Abstract available

    June 2018
    Understanding Patient Adherence and Concerns with STatins and MedicatION Discussions With Physicians (ACTION): A survey on the patient perspective of dialogue with healthcare providers regarding statin therapy.
    Clin Cardiol. 2018;41:710-720.
    PubMed     Abstract available

    May 2018
  14. LEHTOLA H, Hartikainen J, Hartikainen P, Kiviniemi T, et al
    How do anticoagulated atrial fibrillation patients who suffer ischemic stroke or spontaneous intracerebral hemorrhage differ?
    Clin Cardiol. 2018 May 10. doi: 10.1002/clc.22935.
    PubMed     Abstract available

  15. PERREAULT S, Shahabi P, Cote R, Dumas S, et al
    Rationale, design, and preliminary results of the Quebec Warfarin Cohort Study.
    Clin Cardiol. 2018;41:576-585.
    PubMed     Abstract available

    March 2018
  16. FIGLIUZZI I, Presta V, Citoni B, Miceli F, et al
    Achievement of multiple therapeutic targets for cardiovascular disease prevention: Retrospective analysis of real practice in italy.
    Clin Cardiol. 2018 Mar 31. doi: 10.1002/clc.22955.
    PubMed     Abstract available

  17. LI X, Gao L, Wang Z, Guan B, et al
    Lipid profile and incidence of atrial fibrillation: A prospective cohort study in China.
    Clin Cardiol. 2018;41:314-320.
    PubMed     Abstract available

  18. NAJJAR RS, Moore CE, Montgomery BD
    A defined, plant-based diet utilized in an outpatient cardiovascular clinic effectively treats hypercholesterolemia and hypertension and reduces medications.
    Clin Cardiol. 2018;41:307-313.
    PubMed     Abstract available

  19. CESENA FHY, Laurinavicius AG, Valente VA, Conceicao RD, et al
    Low-density lipoprotein-cholesterol lowering in individuals at intermediate cardiovascular risk: Percent reduction or target level?
    Clin Cardiol. 2018;41:333-338.
    PubMed     Abstract available

  20. SEGURO F, Rabes JP, Taraszkiewicz D, Ruidavets JB, et al
    Genetic diagnosis of familial hypercholesterolemia is associated with a premature and high coronary heart disease risk.
    Clin Cardiol. 2018;41:385-391.
    PubMed     Abstract available

  21. ELLIS KL, Pang J, Chieng D, Bell DA, et al
    Elevated lipoprotein(a) and familial hypercholesterolemia in the coronary care unit: Between Scylla and Charybdis.
    Clin Cardiol. 2018;41:378-384.
    PubMed     Abstract available

    January 2018
  22. BUDOFF M, Brent Muhlestein J, Le VT, May HT, et al
    Effect of Vascepa (icosapent ethyl) on progression of coronary atherosclerosis in patients with elevated triglycerides (200-499 mg/dL) on statin therapy: Rationale and design of the EVAPORATE study.
    Clin Cardiol. 2018 Jan 24. doi: 10.1002/clc.22856.
    PubMed     Abstract available

  23. HELOU TN, Santos RD, Laurinavicius AG, Bittencourt MS, et al
    Association between clinical factors and self-underestimation of cardiovascular risk in subjects submitted to a routine health evaluation.
    Clin Cardiol. 2018 Jan 22. doi: 10.1002/clc.22841.
    PubMed     Abstract available

    December 2017
  24. LAHTELA HM, Bah A, Kiviniemi T, Nammas W, et al
    Outcome of octogenarians with atrial fibrillation undergoing percutaneous coronary intervention: insights from the AFCAS registry.
    Clin Cardiol. 2017 Dec 15. doi: 10.1002/clc.22821.
    PubMed     Abstract available

    April 2017
  25. BAUM SJ, Toth PP, Underberg JA, Jellinger P, et al
    PCSK9 inhibitor access barriers-issues and recommendations: Improving the access process for patients, clinicians and payers.
    Clin Cardiol. 2017;40:243-254.
    PubMed     Abstract available

    March 2017
  26. HASSAN VIRK HU, Qureshi WT, Makkar N, Bastawrose J, et al
    Short- and long-term clinical predictors of pharmacological cardioversion of persistent atrial fibrillation by dofetilide: A retrospective cohort study of 160 patients.
    Clin Cardiol. 2017 Mar 14. doi: 10.1002/clc.22680.
    PubMed     Abstract available

    September 2016
  27. ADEDINSEWO D, Taka N, Agasthi P, Sachdeva R, et al
    Prevalence and Factors Associated With Statin Use Among a Nationally Representative Sample of US Adults: National Health and Nutrition Examination Survey, 2011-2012.
    Clin Cardiol. 2016;39:491-6.
    PubMed     Abstract available

    April 2016
  28. BITTENCOURT MS, Staniak HL, Pereira AC, Santos IS, et al
    Implications of the New US Cholesterol Guidelines in the Brazilian Longitudinal Study of Adult Health (ELSA-Brasil).
    Clin Cardiol. 2016;39:215-22.
    PubMed     Abstract available

Thank you for your interest in scientific medicine.

AMEDEO Dyslipidemia is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.